Literature DB >> 2861106

Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects.

M E Kraenzlin, S M Wood, M Neufeld, T E Adrian, S R Bloom.   

Abstract

SMS 201 995 is a new long acting analogue of somatostatin. We have investigated its effect on basal and meal stimulated secretion of gut hormones and have shown that after a single s.c. injection of 50 micrograms it lowers significantly the basal plasma levels of pancreatic polypeptide, secretin, motilin, pancreatic glucagon and insulin, it also effectively suppresses the postprandial release of pancreatic polypeptide, gastrin, secretin, gastric inhibitory peptide, pancreatic glucagon and insulin. Except for the usual brief discomfort of an injection, no symptoms or untoward effects were observed.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2861106     DOI： 10.1007/BF02012573

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  15 in total

1.  D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule.

Authors:  J Rivier; M Brown; W Vale
Journal:  Biochem Biophys Res Commun       Date:  1975-07-22       Impact factor: 3.575

2.  Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

Authors:  S R Bloom; C H Mortimer; M O Thorner; G M Besser; R Hall; A Gomez-Pan; V M Roy; R C Russell; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

3.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

Review 4.  Somatostatin--a regulatory modulator connecting nutrient entry and metabolism.

Authors:  V Schusdziarra
Journal:  Horm Metab Res       Date:  1980-11       Impact factor: 2.936

5.  The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin.

Authors:  J C Frölich; Z T Bloomgarden; J A Oates; J E McGuigan; D Rabinowitz
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

6.  Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor.

Authors:  T M Siler; S C Yen; W Vale; R Guillemin
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

7.  Effects of somatostatin on the secretion of thyrotropin and prolactin.

Authors:  W Vale; C Rivier; P Brazeau; R Guillemin
Journal:  Endocrinology       Date:  1974-10       Impact factor: 4.736

8.  Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.

Authors:  R G Long; A J Barnes; T E Adrian; C N Mallinson; M R Brown; W Vale; J E Rivier; N D Christofides; S R Bloom
Journal:  Lancet       Date:  1979-10-13       Impact factor: 79.321

9.  Somatostatin: analogs with selected biological activities.

Authors:  M Brown; J Rivier; W Vale
Journal:  Science       Date:  1977-06-24       Impact factor: 47.728

10.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728
View more
  11 in total

Review 1.  Pathophysiology, diagnosis and management of postoperative dumping syndrome.

Authors:  Jan Tack; Joris Arts; Philip Caenepeel; Dominiek De Wulf; Raf Bisschops
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

2.  Inhibition by SMS 201-995 of normal mammary gland growth in mice.

Authors:  H Nagasawa; J Nakayama; H Namiki
Journal:  Experientia       Date:  1987-04-15

3.  Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.

Authors:  H J Balks; J M Conlon; W Creutzfeldt; F Stöckmann
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.

Authors:  R Candrina; G Giustina
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

5.  Pilot study of sandostatin (octreotide) therapy of refractory HIV-associated diarrhea.

Authors:  M Fanning; M Monte; L R Sutherland; M Broadhead; G F Murphy; A G Harris
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

6.  Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.

Authors:  P Nubiola; J M Badia; F Martinez-Rodenas; M J Gil; M Segura; J Sancho; A Sitges-Serra
Journal:  Ann Surg       Date:  1989-07       Impact factor: 12.969

7.  Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects.

Authors:  M E Kraenzlin; S M Wood; M Neufeld; T E Adrian; S R Bloom
Journal:  Experientia       Date:  1985-06-15

Review 8.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Effect of secretin and somatostatin on secretion of epidermal growth factor from Brunner's glands in the rat.

Authors:  P S Olsen; P Kirkegaard; S S Poulsen; E Nexø
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

Review 10.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.